Patent intelligence · US
US 12234294
Pharmaceutical composition of a humanized anti-CD40 antibody
Pharmaceutical composition of a humanized anti-CD40 antibody
Patent details — US 12234294
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 25, 2025
- Expiration
- Feb 20, 2045
- Applicant
- Kiniksa Pharmaceuticals, GmbH
- Claims
- 8
- CPC classes
- A61K, A61K39/39591, A61K47/183, A61K9/0019
Quick answer
US 12234294 (Pharmaceutical composition of a humanized anti-CD40 antibody) is held by Kiniksa Pharmaceuticals, GmbH. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kiniksa Pharmaceuticals, GmbH
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K39/39591, A61K47/183, A61K9/0019
More from Kiniksa Pharmaceuticals, GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12122837
Oncostatin M receptor antigen binding proteins
granted -
US 11141479
Stable anti-OSMR antibody formulation
granted -
US 10493149
Stable anti-OSMR antibody formulation
granted -
US 10421813
Oncostatin M receptor antigen binding proteins
granted -
US 10391170
Stable anti-OSMR antibody formulation
granted -
US 9738721
Oncostatin M receptor antigen binding proteins
granted -
US 9663571
Oncostatin M receptor antigen binding proteins
granted
Frequently asked questions
What is US patent 12234294?
US 12234294 (Pharmaceutical composition of a humanized anti-CD40 antibody) is held by Kiniksa Pharmaceuticals, GmbH. Status: granted. Granted Feb 25, 2025. Expires Feb 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12234294?
Kiniksa Pharmaceuticals, GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12234294 expire?
Our index shows an expiration date of Feb 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.